Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Clinical Trials Information Group officer
CONTACT
Qingyuan Zhang, M.D.
CONTACT
Lead
CSPC Megalith Biopharmaceutical Co.,Ltd.
This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer. The study aims to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of SYS6023 in combination with other agents in subjects with advanced breast cancer. Eligible subjects will receive SYS6023 in combination with HB1901 or KN026, with each treatment cycle lasting 3 weeks, until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of informed consent, loss to follow-up, or death, whichever occurs first.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted